Table 1.
Characteristics of enrolled patients and treatment course outcomes.
| Patient # | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age | 52 | 29 | 18 | 40 | 31 | 37 | 36 | 46 | 26 | 24 | 37 | 40 |
| Sex | F | F | M | F | M | M | F | F | F | M | F | F |
| Race | Caucasian | Caucasian | Hispanic | Caucasian | African | African | Hispanic | African | Hispanic | Caucasian | African | Caucasian |
| Duration of current episode of scalp hair loss | 3 years | 1 year | 2 years | 4 years | 30 years | 33–34 years | 10 years | 3 years | 2–3 years | 1 year | 5 years | 20 years |
| Total duration patiant has had alopecia areata | 3 years | 7 years | 3 years | 5 years | 30 years | 33–34 years | 17 years | 20 years | 20 years | 4 years | 16 years | 33 years |
| Total duration of AT/AU (if patient has AT/AU) | 1 year | N/A | N/A | N/A | 30 years | N/A | 6 years | n/a | n/a | 1 year | 4 years | n/a |
| Weeks of dose escelation(s) | 20,28 | 20,32 | 26,32 | N/A | 18,26 | 16 | 12,20 | n/a | 8,16 | 8,16 | 4,12 | 5,12 |
| Week treatment was stopped | 48 | 41 | 38 | 24 | 36 | 24 | 54 | 12 | 48 | 64 | 50 | 25 |
| Baseline SALT (%) score | 100 | 46 | 49 | 84 | 100 | 58 | 100 | 92 | 52 | 100 | 100 | 95 |
| Lowest SALT (%) score achieved | 15 | 11 | 19 | 0 | 99 | 50 | 50 | 80 | 3 | 21 | 13 | 86.5 |
| Week lowest SALT (%) score was achieved | 48 | 40 | 36 | 24 | 20 | 24 | 68 | 12 | 48 | 44 | 40 | 20 |
| Greatest regrowth percentage of SALT (%) score achieved | 85.0 | 76.1 | 61.2 | 100.0 | 1.0 | 13.8 | 50.0 | 13.0 | 94.2 | 79.0 | 87.0 | 8.9 |
| Patient outcome | Responder, Dropped out | Responder | Responder, lost to follow up | Responder | Nonresponder | Nonresponder | Responder | Dropped out | Responder | Responder | Responder | Nonresponder |
| Clinical durability of response * | N/a | 7 weeks | N/a | 8–16 weeks | N/a | N/a | 14 weeks | N/a | 8–16 weeks | 24 weeks | 10–26 weeks | N/a |
| Absolute durability of response** | N/a | 7–15 weeks | N/a | 8–16 weeks | N/a | N/a | 22 weeks | N/a | 16 weeks | 24 weeks | 26 weeks | N/a |
*
Clinical durability of response is defined as the minimum observed time a responder maintained 50% regrowth after the treatment drug has been discontinued. This accounts for the amount of durability that is clinically significant as it only considers duration in which a patient would still quality as a “responder” upon discontinuation of drug.
**
Absolute durability of response is defined as the minimum observed time a responder maintained a SALT score that was below the patients’ baseline SALT score after the treatment drug has been discontinued. In some cases, there is a range of dates which reflect that this was an outcome that occurred while the patient was between visits.